Confidence in Every Seal: LigaSure™ RAS Now Available on the Hugo™ Robotic‑Assisted Surgery System ^1,4,5

Robotic‑assisted surgery continues to evolve, with increasing focus on precision, efficiency, and surgeon choice. One of the most critical elements of any minimally invasive procedure—robotic or laparoscopic—remains reliable vessel sealing. With the launch of LigaSure™ RAS Maryland, surgeons now have access to LigaSure™ vessel sealing technology, available as a robotically driven instrument on the Hugo™ Robotic‑Assisted Surgery (RAS) System.

A Trusted Technology Enters Robotic‑Assisted Surgery⁶

LigaSure™ technology has been used in more than 35 million procedures worldwide, earning surgeon confidence across multiple specialties over more than two decades.⁶ The introduction of LigaSure™ RAS Maryland brings this established advanced energy platform into robotic‑assisted surgery, combining proven vessel sealing performance with the flexibility and modularity of the Hugo™ RAS system.^6,7

Since its Australian launch in September 2025, LigaSure™ RAS has already been used in 66 robotic cases, reflecting early adoption across a broad range of procedures. These include hysterectomies, endometriosis, hernia repairs, gastric bypass procedures, fundoplication, sacrocolpopexy, prostatectomy, and colectomies. This early experience highlights the versatility of the device across both pelvic and abdominal robotic surgery.

Designed for Reliable Sealing and Precise Dissection^1,4,5,7,10

At its core, LigaSure™ RAS Maryland is engineered to deliver consistent, vessel sealing in robotic procedures. ^1,4,5,7,10 The device is capable of sealing vessels up to 7 mm in diameter, meeting the LigaSure™ performance standard of burst pressures up to 360 mmHg when used with the Valleylab™ FT10 energy platform. ^4,5,10

Beyond vessel sealing, the Maryland jaw design supports a multifunctional surgical workflow. The instrument enables effective ligation and division of vessels, thick tissue bundles, and lymphatics, while also supporting cold cutting when required. ^1,9,10 Surgeons can utilise the device for secure grasping, blunt dissection, and tissue manipulation, with curved jaws designed to improve access compared with straight‑jaw instruments. ^1,9,10

This multifunctionality may reduce the need for frequent instrument exchanges, supporting procedural efficiency and maintaining surgical flow during robotic cases. ^1,9,10

Integrated with the Hugo™ RAS System

LigaSure™ RAS Maryland has been developed specifically for compatibility with the Hugo™ RAS System, which features independent arm carts, a modular system architecture, and three‑dimensional visualisation. ^1,9,10 These design elements aim to support flexible operating room set‑up, improved access to anatomy, and enhanced ergonomics for the operating surgeon. ^1,9,10

As robotic platforms continue to expand across specialties*, integrating trusted technologies into these systems remains critical. With LigaSure™ RAS Maryland, surgeons can access the confidence of a proven vessel sealing technology—now purpose‑built for robotic‑assisted surgery and already demonstrating early clinical uptake across Australia.

To learn more, book a demo today.

*Disclaimer: In Australia, HugoTM robotic-assisted surgery system is currently indicated for certain urology, gynaecology, and general surgery laparoscopic surgical procedures. (Please refer to the User Guide for a full list of specified procedures).

References:

¹Based on internal test report RE00S40481, LigaSure™ RAS Maryland jaw sealer/divider surgeon validation marketing report. Based on porcine model. April 26–May 3, 2024. 

²LigaSure™ RAS Maryland instructions for use (3'. Medtronic; 2024:S.)

³Based on internal test report RE00476319, LigaSure™ RAS Maryland jaw sealer/divider in acute hemostasis and thermal spread porcine study. Table 1. October 19, 2019. 

⁴Based on internal test report RE00476260, Marystein bench top tissue study. Table 1. August 15, 2024. 

⁵Based on internal test report RE00476323, LigaSure™ RAS Maryland jaw sealer/divider in chronic hemostasis porcine study. December 9, 2023. 

⁶Based on internal sales data from FY01–FY23. November 2023. 

⁷16 of 16 surgeons surveyed after use agreed. 

⁸Bench tissue and animal model may not be indicative of clinical tissue performance

⁹15 of 16 surgeons surveyed after use agreed. 

¹⁰Compared to procedures without a vessel sealer.

Approval number: AU-SE-2600011